Drug interactions have become a significant iatrogenic complication, with as many as 5% of hospitalizations and 7,000 deaths annually attributable to drug-drug interactions in the United States. There are several reasons these numbers have increased. First, many new medications have been brought to market in recent years. Second, advances in medical care have resulted in increased longevity and more elderly patients than ever before -- patients who are more likely to be following polypharmacy regimens. Population patterns in the U.S. have amplified this trend, with aging baby boomers swelling the patient pool and demanding treatment with medications advertised on television and in print.

ContributorsPrefaceAcknowledgmentsPART I: Introduction and Basic Pharmacology of Metabolic Drug InteractionsChapter 1. Introduction to Drug Interactions and to This Clinical ManualChapter 2. Definitions and Phase I MetabolismChapter 3. Metabolism in Depth: Phase IIChapter 4. TransportersPART II: P450 EnzymesIntroduction to Part IIChapter 5. 2D6Chapter 6. 3A4Chapter 7. 1A2Chapter 8. 2C9Chapter 9. 2C19Chapter 10. 2E1Chapter 11. 2A6, 2B6, and 2C8PART III: Drug Interactions by Medical SpecialtyChapter 12. Gynecology: Oral Contraceptives Chapter 13. Internal MedicineChapter 14. Infectious DiseasesChapter 15. NeurologyChapter 16. OncologyChapter 17. Pain Management I: Nonnarcotic AnalgesicsChapter 18. Pain Management II: Narcotic AnalgesicsChapter 19. PsychiatryChapter 20. Transplant Surgery and Rheumatology: ImmunosuppressantsPART IV: Practical MattersChapter 21. GuidelinesChapter 22. Medicolegal Implications of Drug-Drug InteractionsChapter 23. How to Retrieve and Review the LiteratureAppendix: Tables of Drug Interaction PharmacokineticsIndex